Glass et al. [211] used NGS platform to identify MECOM (previously EVI1) target genes by comparison in MECOM-overexpressing murine myeloid leukemia cell lines (DA-1, NFS-60) before and after shRNA-mediated MECOM knockdown. MECOM, oncogenic transcription factor associated with human myeloid malignancies of poor prognosis, is overexpressed in 8–10% of adult AML and up to 27% of pediatric leukemias with KMT2A rearrangements. MECOM-induced leukemic cells present impaired myeloid differentiation, resistance to apoptosis, and aberrant cell cycle regulation, which results in excessive proliferation. Here, MECOM is linked to acute myeloid leukemia.